55,90 €
Royal Peptides – CJC-1295 5mg + Ipamorelin 5mg (Lyophilized Powder)
A premium research combination of two highly pure peptide secretagogues in an optimal 1:1 ratio, supplied as a stable lyophilized powder in a protective vial. CJC-1295 + Ipamorelin is a fixed blend designed for advanced biomedical studies focused on endocrine regulation and stimulation of the growth hormone (GH) axis. The combination of a GHRH analog and a selective ghrelin receptor agonist produces a well-documented synergistic effect, which in laboratory models stimulates pulsatile release of endogenous growth hormone, supports protein synthesis, accelerates cellular regeneration, and optimizes body composition without disrupting hormonal homeostasis. This product is intended exclusively for scientific, laboratory, and research purposes.
40 in stock
CJC-1295 5mg + Ipamorelin 5mg – lyophilized powder (Ultimate Synergistic GH-Secretagogue Blend)
A fixed combination of CJC-1295 (without DAC) and Ipamorelin represents one of the most respected laboratory models in the field of regenerative medicine research, metabolic optimization, and anti-aging science. This product combines 5 mg of CJC-1295 and 5 mg of Ipamorelin into a single homogeneous lyophilized “cake” (a total of 10 mg of active substance in the vial). In scientific protocols, this pair is studied exclusively together due to their complementary pharmacodynamics: instead of a linear summation of effects, these two molecules demonstrate an exponential synergy after reconstitution, capable of maximizing pituitary response while preserving the natural pulsatile biology of the test subject.
Lyophilization (freeze-drying under vacuum) ensures extreme stability of amino acid chains and protects them from degradation prior to the reconstitution (dissolution) process in an appropriate buffer or bacteriostatic medium.
Research-Observed Effects
The fundamental pillar of research into this blend is the dual stimulation of somatotrophic cells in the anterior pituitary gland:
Synergistic increase in growth hormone: CJC-1295 acts as an analog of natural GHRH (Growth Hormone Releasing Hormone) and binds to GHRH receptors, priming cells for secretion. Ipamorelin simultaneously acts as a pure agonist of growth hormone secretagogue receptors (GHS-R / ghrelin receptors), triggering secretion itself while suppressing somatostatin (the hormone that inhibits GH release). The resulting GH pulse in studies is significantly stronger than when the substances are administered individually.
Absolute selectivity without hormonal side effects: Unlike older secretagogues (such as GHRP-2 or GHRP-6), Ipamorelin shows zero affinity in in vivo models for receptors that stimulate cortisol (stress hormone) or prolactin secretion. This allows research to proceed without unwanted endocrine interference.
Support of anabolic and reparative processes from within: Increased pulsation of endogenous growth hormone subsequently stimulates the liver to produce IGF-1 (insulin-like growth factor). This process is studied in the context of accelerated healing of bones, tendons, and muscle tissues, enhanced protein synthesis, and rapid cellular regeneration.
Metabolic and lipolysis optimization: Research teams analyze the effect of this blend on adipocytes, where elevated GH levels proactively stimulate fatty acid oxidation (fat burning) and improve cellular sensitivity to nutrients.
Scientific context and research references
The mechanisms of synergy between GHRH analogs and ghrelin mimetics were first described in the 1990s and have since become a stable foundation of neuroendocrine research. Studies confirm that this combination closely mimics the body’s natural physiological pulses, thereby preventing receptor exhaustion or desensitization in the pituitary gland.
Hundreds of peer-reviewed publications and clinical models focusing on pharmacokinetics, cellular signaling, and the impact of these peptides on bone density and muscle hypertrophy are fully indexed and available to the scientific community in the international PubMed database (search terms: “CJC-1295 Ipamorelin synergy”, “GHRH and GHRP co-administration”, or “Ipamorelin receptor selectivity”).
Precise data on lyophilized stability, sequence purity, and long-term effects of secretagogues on the endogenous endocrine profile of test subjects are continuously monitored and updated in academic study proposals on ClinicalTrials.gov.
The Royal Peptides vial contains 10 mg of ultra-pure, laboratory-verified blend (5 mg CJC-1295 + 5 mg Ipamorelin) prepared for immediate reconstitution under strictly controlled scientific conditions.
